Alnylam Pharmaceuticals Inc (ALNY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Alnylam Pharmaceuticals Inc (Alnylam) is a biopharmaceutical company, which discovers, develops, and commercializes drugs based on RNAi interference. The company’s marketed RNAi therapies include Onpattro, which is used in the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis; Givlaari for acute hepatic porphyria, Amvuttra, for the treatment of ATTR amyloidosis with cardiomyopathy; and Oxlumo for primary hyperoxaluria type 1 (PH1). The company develops a broad pipeline of investigational RNAi drugs in the areas of genetic medicines, hepatic infectious, cardio-metabolic, and central nervous system (CNS) diseases. Its late-stage product candidates include vutrisiran for ATTR amyloidosis, inclisiran for hypercholesterolemia, fitusiran for hemophilia and rare bleeding disorders, and lumasiran for severe PH1. The company operates subsidiaries in North America, Europe and Asia-Pacific. Alnylam is headquartered in Cambridge, Massachusetts, the US.Alnylam Pharmaceuticals Inc Key Recent Developments
- Apr 06, 2023: Alnylam Pharmaceuticals Publishes 2022 Annual Report
- Mar 09, 2023: Alnylam Pharmaceuticals and Medison Pharma announce the expansion of their collaboration to a multi-regional partnership to commercialize RNAi therapeutics
- Mar 08, 2023: Alnylam Announces Appointment of Peter Kellogg to Board of Directors
- Mar 03, 2023: Alnylam Named One of Fast Company's Most Innovative Companies for 2023
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Section 1 - About the Company
Section 2 - Company Analysis
Section 3 - Company Financial Ratios
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Section 5 - Company’s Recent Developments
Section 6 - Appendix
List of Tables
List of Figures
Samples
LOADING...
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- OliX Pharmaceuticals Inc
- Ochre Bio Ltd
- Sylentis SAU
- F. Hoffmann-La Roche Ltd
- Dyne Therapeutics Inc
- Wave Life Sciences Ltd
- Phio Pharmaceuticals Corp
- Horizon Therapeutics Plc
- BIOPATH Laboratoires
- Quark Pharmaceuticals Inc
- Eli Lilly and Co
- Biomics Biopharma Ltd
- Arrowhead Pharmaceuticals Inc
- Arcturus Therapeutics Holdings Inc
- Sylentis SAU
- ProQR Therapeutics NV
- DTx Pharma Inc
- Amgen Inc
- F. Hoffmann-La Roche Ltd
- Atalanta Therapeutics Inc
- AstraZeneca Plc
- Takeda Pharmaceutical Co Ltd
- Silenseed Ltd
- Silence Therapeutics Plc
- Janssen Pharmaceutical
- Boehringer Ingelheim Pharma GmbH & Co KG
- SixFold Bioscience Ltd
- Novo Nordisk AS
- Mallinckrodt Plc
- Jiangsu Hansoh Pharmaceutical Group Co Ltd
- GSK plc
- Avidity Biosciences Inc
- Ascletis Pharma Inc
- Arbutus Biopharma Corp
- Arrowhead Pharmaceuticals Inc
- Quark Pharmaceuticals Inc
- Pfizer Inc